Brokerage firm Motilal Oswal has initiated coverage on Aster DM Healthcare with a 'Buy' rating and a target price of ₹910. The report highlights the merger with Quality Care India Limited as a key growth driver, aiming to build a larger pan-India hospital network. Investors should track the company’s ability to successfully merge operations, as future growth estimates depend on achieving promised cost and clinical efficiencies.
Motilal Oswal has officially started tracking Aster DM Healthcare, issuing a 'Buy' rating with a price target of ₹910. This development comes as the company focuses on its post-merger integration with Quality Care India Limited. The brokerage views this merger as a turning point that helps the hospital operator establish a more significant footprint across the Indian market.
The combined entity currently operates 39 hospitals, managing roughly 10,600 beds. The growth strategy outlined in the brokerage report suggests a roadmap to scale capacity to over 15,000 beds in the coming years. This plan relies on a strategy of clustering hospitals in key states like Kerala, Karnataka, Maharashtra, and the Telangana-Andhra Pradesh region, where the company aims to balance stable revenue from established centers with high-growth potential in newer markets.
Financial estimates provided by the brokerage project proforma combined revenue to reach approximately ₹9,270 crore for FY26, with an estimated EBITDA of ₹2,000 crore. The research note forecasts a compound annual growth rate for revenue at 19.5% and EBITDA at 25% through FY28. However, these figures assume that the company successfully captures the intended cost savings and operational benefits from merging with Quality Care India Limited.
Investors should be aware of several operational and sector-specific risks. Integrating a large new business carries execution risks, such as potential delays in ramping up bed capacity or operational bottlenecks. If the expected synergies—the financial benefits and savings gained from combining the two companies—are not realized as planned, it could impact profit margins and returns on capital. Furthermore, the Indian hospital sector remains sensitive to government regulations, including price caps on medical procedures, which can limit pricing power and affect profitability.
Looking ahead, the market will likely focus on how effectively the management executes the integration process. Key monitorables for investors include the occupancy rates of the newly integrated facilities, the pace of bed additions, and whether the company can maintain stable margins while managing the debt or capital requirements associated with such large-scale expansion. Any deviation from the projected timeline for synergy realization or a change in regulatory policy regarding hospital pricing may lead to volatility in performance expectations.